Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2010

01-08-2010 | Original Article

Predictive Power of Serum Pepsinogen Tests for the Development of Gastric Cancer in Comparison to the Histologic Risk Index

Authors: Min Sun Kwak, Nayoung Kim, Hye Seung Lee, Hee Eun Lee, Hyun Chae Jung, In Sung Song

Published in: Digestive Diseases and Sciences | Issue 8/2010

Login to get access

Abstract

Background and Aim

The selection of a high-risk group of gastric cancer is important. This study was performed to compare the efficacy of non-invasive gastric cancer screening through the measurement of pepsinogen (PG) I/II ratio and endoscopic screening using histologic criteria (Meining’s risk index for gastric cancer) in Korean patients.

Methods

Included in the study were 460 gastric cancer patients and 460 control cases who underwent upper endoscopy between June 2003 and July 2008 at Seoul National University Bundang Hospital. Serum PG I/II ratio and histologic characteristics were evaluated for each participant. Multivariate logistic regression was performed to compare the predictive power for gastric cancer of both the PG II/I ratio (the inverse form of PG I/II ratio) and the histologic gastric cancer risk index.

Results

A higher PG II/I ratio was significantly associated with a higher risk for gastric cancer (odds ratio of highest quartile for cancer vs. lowest quartile, 3.51; 95% confidence interval, 2.29–5.36) in the multivariate logistic model. The validity (in terms of calibration and discrimination) of the PG-including multivariate logistic model was comparable to the histologic gastric cancer risk index model. The results were similar regardless of the staging of the cancer, Lauren’s histologic classification, and the location of the cancer.

Conclusions

These results suggest that non-invasive measurement of serum PG I/II ratio is as effective as Meining’s histologic gastric cancer risk index in predicting gastric cancer occurrence.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
2.
Kunisaki C, Ishino J, Nakajima S, et al. Outcomes of mass screening for gastric carcinoma. Ann Surg Oncol. 2006;13:221–228.CrossRefPubMed
3.
Hosokawa O, Miyanaga T, Kaizaki Y, et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol. 2008;43:1112–1115.CrossRefPubMed
4.
Meining A, Bayerdorffer E, Muller P, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998;432:311–314.CrossRefPubMed
5.
Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–253.CrossRefPubMed
6.
Mizoue T, Yoshimura T, Tokui N, et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer. 2003;106:103–107.CrossRefPubMed
7.
Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–768.CrossRefPubMed
8.
9.
Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302–1305.CrossRefPubMed
10.
Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–143.CrossRefPubMed
11.
Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.PubMedCrossRef
12.
The EUROGAST study group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341:1359–1362.CrossRef
13.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.CrossRefPubMed
14.
Hirata Y, Maeda S, Mitsuno Y, et al. Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation. Gastroenterology. 2002;123:1962–1971.CrossRefPubMed
15.
Goto T, Haruma K, Kitadai Y, et al. Enhanced expression of inducible nitric oxide synthase and nitrotyrosine in gastric mucosa of gastric cancer patients. Clin Cancer Res. 1999;5:1411–1415.PubMed
16.
Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G. Serum pepsinogen in screening for gastric cancer. J Gastroenterol. 1995;30:452–460.CrossRefPubMed
17.
Borch K, Axelsson CK, Halgreen H, Damkjaer Nielsen MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol. 1989;24:870–876.CrossRefPubMed
18.
Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology. 1971;61:185–188.PubMed
19.
Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973;65:36–42.PubMed
20.
Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83:204–209.PubMed
21.
Miki K, Ichinose M, Kakei N, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol. 1995;362:139–143.PubMed
22.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.CrossRefPubMed
23.
Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. clinical classification. Jpn J Surg. 1981;11:127–139.CrossRefPubMed
24.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
25.
Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol. 1991;165:69–73.CrossRefPubMed
26.
Kim SY, Ahn JS, Ha YJ, et al. Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. J Immunoassay. 1998;19:251–270.CrossRefPubMed
27.
Kullavanijaya P, Thong-Ngam D, Hanvivatvong O, Nunthapisud P, Tangkijvanich P, Suwanagool P. Analysis of eight different methods for the detection of Helicobacter pylori infection in patients with dyspepsia. J Gastroenterol Hepatol. 2004;19:1392–1396.CrossRefPubMed
28.
Andersen LP, Kiilerick S, Pedersen G, et al. An analysis of seven different methods to diagnose Helicobacter pylori infections. Scand J Gastroenterol. 1998;33:24–30.PubMed
29.
Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology. 1991;101:167–174.PubMed
30.
Kokkola A, Kosunen TU, Puolakkainen P, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS. 2003;111:619–624.CrossRefPubMed
31.
Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2008;13:146–156.CrossRefPubMed
32.
Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:2874–4873.
33.
Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–287.CrossRefPubMed
34.
Imagawa S, Yoshihara M, Ito M, et al. Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study. Dig Dis Sci. 2008;53:1818–1823.CrossRefPubMed
35.
Mabogunje OA, Subbuswamy SG, Lawrie JH. The two histological types of gastric carcinoma in northern Nigeria. Gut. 1978;19:425–429.CrossRefPubMed
36.
Di Mario F, Cavallaro LG, Moussa AM, et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci. 2006;51:1791–1795.CrossRefPubMed
37.
Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–766.PubMed
38.
Korstanje A, van Eeden S, Offerhaus JA, et al. Comparison between serology and histology in the diagnosis of advanced gastric body atrophy: a study in a Dutch primary community. J Clin Gastroenterol. 2008;42:18–22.CrossRefPubMed
39.
Bodger K, Wyatt JI, Heatley RV. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter. 2001;6:216–224.CrossRefPubMed
40.
Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007;12:333–340.CrossRefPubMed
Metadata
Title
Predictive Power of Serum Pepsinogen Tests for the Development of Gastric Cancer in Comparison to the Histologic Risk Index
Authors
Min Sun Kwak
Nayoung Kim
Hye Seung Lee
Hee Eun Lee
Hyun Chae Jung
In Sung Song
Publication date
01-08-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1181-x

Other articles of this Issue 8/2010

Digestive Diseases and Sciences 8/2010 Go to the issue

Original Article

Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease

Original Article

Sirolimus Attenuates Reduced-Size Liver Ischemia–Reperfusion Injury But Impairs Liver Regeneration in Rats

Original Article

Long-Term Repopulation Effects of Donor BMDCs on Intestinal Epithelium

Original Article

A Feasibility Study of Probiotics Pretreatment as a Bowel Preparation for Colonoscopy in Constipated Patients

Original Article

Effect of Azithromycin on Acute Inflammatory Lesions and Colonic Bacterial Load in a Murine Model of Experimental Colitis

Original Article

Diagnosis and Prognostic Significance of Minimal Hepatic Encephalopathy in Patients with Cirrhosis of Liver
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits